Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window

NCT ID: NCT03094715

Last Updated: 2023-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

253 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-20

Study Completion Date

2023-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of symptom onset). Up to 665 subjects will be randomized. Primary endpoint will be functional outcome assessed by the modified Rankin scale at 90 days post-stroke ("mRS shift analysis"). By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute stroke population with uncertain benefit of endovascular stroke treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a prospective, open label, blinded endpoint (PROBE),European, two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke (AIS) in patients with extended stroke lesions defined by an ASPECT score of 3-5 and in an extended time window (up to 12 hours, or unknown time of symptom onset). This is an adaptive design study, with prospectively stated interim analyses with specified stopping rules allowing for the possibility early termination based on either a determination of study success or futility.

Up to 665 subjects will be enrolled in the study and randomized for the Intention to treat analysis set. The randomization will be stratified by time from symptom onset (0-6h and 6-11h/wake up stroke), and stroke severity (NIHSS ≤18, NIHSS \>18).

Interim data analysis is planned after the primary endpoint has been obtained for one third and two thirds of the patients. At each of these sample sizes, the available 90-day mRS data for each treatment arm will be evaluated. Safety interim analysis will be performed after one third and two thirds of the patients have been included.

Subjects who meet the inclusion criteria will be randomized in a 1:1 ratio to one of the following two treatment arms:

Arm 1: best medical care Arm 2: endovascular thrombectomy and best medical care The primary objective of this study is to test efficacy and safety of thrombectomy in acute stroke patients with uncertain benefit of endovascular stroke treatment, i.e. extended ischemic lesion size with an ASPECT score of 3-5 or late (up to 12 hours) or unknown time window as compared to best medical care alone.

Approximately 40 sites in Up to 20 sites in 8-10 European countries Patients presenting with acute ischemic stroke (AIS) based on focal occlusion in the M1 segment of the middle cerebral artery (MCA), and/or the intracranial segment of the distal internal carotid artery (ICA), determined by Magnetic Resonance Angiography (MRA) or Computed Tomographic Angiography (CTA), and who meet all eligibility criteria will be considered for study enrollment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke, Acute Cerebral Stroke Cerebrovascular Stroke Apoplexy; Brain

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Mechanical thrombectomy Endovascular thrombectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

prospective, open label, blinded endpoint (PROBE), European, two-arm, randomized, controlled, post-market study
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thrombectomy

Endovascular thrombectomy and best medical care

Group Type ACTIVE_COMPARATOR

Thrombectomy

Intervention Type DEVICE

Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).

Best medical care

Best medical treatment

Group Type OTHER

Best medical care

Intervention Type OTHER

Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Thrombectomy

Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).

Intervention Type DEVICE

Best medical care

Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Mechanical thrombectomy Control group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Randomization within 11 hours after stroke onset (if known) or last seen well.
* Endovascular treatment is expected to be finished within 12 hours after known symptom onset or last seen well by judgment of the interventional neuroradiologist in charge (if stroke onset is known).
* Patient must demonstrate clinical signs and symptoms attributable to target area of occlusion consistent with the diagnosis of ischemic stroke, including impairment of the following: language, motor function, sensation, cognition, gaze, and/or vision for at least 30 minutes without relevant improvement.
* Female and male patient above 18 years of age
* NIHSS Score of \<26
* Signed informed consent (IC) form by patient or legal guardian, or inclusion of patient's presumptive will by investigator under emergency situation, but after consultation of an independent physician who is familiar with these types of illness if the other options are not possible according to local approval.
* Prior to new focal neurological deficit, mRS score was ≤2.


* A new focal occlusion confirmed by imaging (MRA/CTA) to be accessible to the thrombectomy device, and located in the M1 of the middle cerebral artery (MCA) and/or the intracranial segment of the distal internal carotid artery (ICA).
* CT (non-contrast CT) or DWI with an ASPECT score of 3-5

Exclusion Criteria

* Patient is an active participant in another drug or device treatment trial for any disease state or patient is expected to start participation in another drug or device treatment trial while enrolled in this protocol, unless approved by Sponsor.
* Patient has pre-existing neurological or psychiatric disease that could impede the study results or would confound the neurological or functional evaluations.
* Patient has vascular disease preventing endovascular treatment (e.g. aortic dissection or aneurysm, no arterial transfemoral access)
* Patient has history of contraindication for contrast medium.
* Patient is known to have infective endocarditis
* Patient's anticipated life expectancy is less than 6 Months12 months


* ExtracaranialExtracranial CT scan or MR angiography showing high grade stenosis expected to require acute stent placement (especially e.g. ICAACI stenting) during the procedure to get access to the occlusion
* CT or MRI with evidence of: Mass mass effect or intracranial tumor, or hypodensity on unenhanced CT and
* If CT perfusion is done per institutional standard: CBV drop on CBV maps on CTP, or, alternatively as with an ASPECT score of 0-2
* If DWI is done per institutional standard,: restricted diffusion on DWI with an ASPECT score of 0-2, or above 5
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Karolinska University Hospital

OTHER

Sponsor Role collaborator

Eppdata GmbH Hamburg, Germany

UNKNOWN

Sponsor Role collaborator

Aarhus University Hospital

OTHER

Sponsor Role collaborator

Medical University Innsbruck

OTHER

Sponsor Role collaborator

Groupe Hospitalier Pitie-Salpetriere

OTHER

Sponsor Role collaborator

Oslo University Hospital

OTHER

Sponsor Role collaborator

University Hospital, Martin

OTHER

Sponsor Role collaborator

Charles University, Czech Republic

OTHER

Sponsor Role collaborator

Hospices Civils de Lyon

OTHER

Sponsor Role collaborator

CHU de Reims

OTHER

Sponsor Role collaborator

Epidemiological and Clinical Research Information Network

OTHER

Sponsor Role collaborator

STROKE ALLIANCE FOR EUROPE

UNKNOWN

Sponsor Role collaborator

International Consortium for Health Outcome Measurement, Inc.

OTHER

Sponsor Role collaborator

Europan Society for Minimally Invasive Neurological Therapy

UNKNOWN

Sponsor Role collaborator

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role collaborator

University Hospital Heidelberg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Martin Bendszus

Central trial management, Coordinating investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Götz Thomalla, MD

Role: STUDY_CHAIR

Coordination and Project Management Tension, Neurology, UKE Hamburg, Germany

Martin Bendszus, MD

Role: PRINCIPAL_INVESTIGATOR

Central Trial Management Tension, Neuroradiology, UHHeidelberg, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Division of Neuroradiology, Vascular and Interventional Radiology, Department of Radiology, Medical University Graz

Graz, , Austria

Site Status

Medical University Innsbruck

Innsbruck, , Austria

Site Status

Neuroradiology, Keppler University Hospital Linz

Linz, , Austria

Site Status

Department of Neurology, Reseach Institute of Neurointervention, Christian Doppler Clinic, Paracelsus Medical University Salzburg

Salzburg, , Austria

Site Status

University of Calgary

Calgary, Alberta, Canada

Site Status

St. Anne's University Hospital Brno

Brno, , Czechia

Site Status

Faculty Hospital Hradec Kralove

Hradec Králové, , Czechia

Site Status

Comprehensive stroke center,University Hospital Ostrava

Ostrava, , Czechia

Site Status

Homolka Hospital Prague

Prague, , Czechia

Site Status

Dept. of Radiology, Masaryk hospital

Ústí nad Labem, , Czechia

Site Status

Aalborg University Hospital

Aalborg, , Denmark

Site Status

Aarhus University Hospital

Aarhus, , Denmark

Site Status

University Hospital Rigshospitalet

Copenhagen, , Denmark

Site Status

CHU Gabriel Montpied, Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Hôpiteaux Universitaires Paris-Sud, Hôpital Bicêtre

Le Kremlin-Bicêtre, , France

Site Status

Hôpital Pitié-Salpêtrière

Paris, , France

Site Status

Université Reims Champagne Ardenne/ Department of Neuroradiology, Hôpital Maison Blanche

Reims, , France

Site Status

CHU de Rennes/Centre Urgences-Réanimations

Rennes, , France

Site Status

CHRU Hôpiteaux de Tours / Hôpital Bretonneau

Tours, , France

Site Status

Universitätsinstitut für Diagnostische Radiologie, Neuroradiologie und Nuklearmedizin Johannes Wesling Klinikum Minden

Minden, North Rhine-Westphalia, Germany

Site Status

Otto-von-Guericke-University Magdeburg

Magdeburg, Saxony-Anhalt, Germany

Site Status

Universitätsklinikum KK Bochum-Langendreer Institut für Diagnostische und Interventionelle Radiologie, Neuroradiologie und Nuklearmedizin

Bochum, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Gesundheit Nord gGmbH Klinikverbund Bremen

Bremen, , Germany

Site Status

Klinik für Radiologie und Neuroradiologie am Klinikum Mitte

Dortmund, , Germany

Site Status

Universitätsklinikum Carl Gustav Carus Dresden

Dresden, , Germany

Site Status

Alfried Krupp Krankenhaus Rüttenscheid

Essen, , Germany

Site Status

Diakonissenkrankenhaus Flensburg

Flensburg, , Germany

Site Status

Universitätsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

Neuroradiologie Universitätsklinikum Heidelberg

Heidelberg, , Germany

Site Status

Universitätsklinikum Leipzig AöR

Leipzig, , Germany

Site Status

UKSH Universitätsklinikum Schleswig-Holstein Campus Lübeck

Lübeck, , Germany

Site Status

Klinikum der Universität München

München, , Germany

Site Status

Technische Universität München / Klinikum rechts der Isar

München, , Germany

Site Status

Universitätsklinikum Würzburg

Würzburg, , Germany

Site Status

Haukeland University Hospital

Bergen, , Norway

Site Status

Oslo University Hospital

Oslo, , Norway

Site Status

The Arctic University of Norway

Tromsø, , Norway

Site Status

Comenius University's Jessenius Faculty of Medicine and University Hospital

Martin, , Slovakia

Site Status

Faculty Hospital Trnava

Trnava, , Slovakia

Site Status

La Paz University Hospital

Madrid, , Spain

Site Status

University Hospital Basel

Basel, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden Austria Canada Czechia Denmark France Germany Norway Slovakia Spain Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Bendszus M, Bonekamp S, Berge E, Boutitie F, Brouwer P, Gizewski E, Krajina A, Pierot L, Randall G, Simonsen CZ, Zelenak K, Fiehler J, Thomalla G. A randomized controlled trial to test efficacy and safety of thrombectomy in stroke with extended lesion and extended time window. Int J Stroke. 2019 Jan;14(1):87-93. doi: 10.1177/1747493018798558. Epub 2018 Aug 29.

Reference Type BACKGROUND
PMID: 30156479 (View on PubMed)

Bendszus M, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenak K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Flottmann F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Mohlenbruch M, Muller-Hulsbeck S, Munnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schonenberger S, Tennoe B, Ulfert C, Valis K, Vitkova E, Vollherbst DF, Wick W, Thomalla G; TENSION Investigators. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial. Lancet. 2023 Nov 11;402(10414):1753-1763. doi: 10.1016/S0140-6736(23)02032-9. Epub 2023 Oct 11.

Reference Type RESULT
PMID: 37837989 (View on PubMed)

van Horn N, Kniep H, Broocks G, Meyer L, Flottmann F, Bechstein M, Gotz J, Thomalla G, Bendszus M, Bonekamp S, Pfaff JAR, Dellani PR, Fiehler J, Hanning U. ASPECTS Interobserver Agreement of 100 Investigators from the TENSION Study. Clin Neuroradiol. 2021 Dec;31(4):1093-1100. doi: 10.1007/s00062-020-00988-x. Epub 2021 Jan 27.

Reference Type RESULT
PMID: 33502563 (View on PubMed)

Winkelmeier L, Kniep H, Thomalla G, Bendszus M, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenak K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Mohlenbruch M, Muller-Hulsbeck S, Munnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schonenberger S, Tennoe B, Ulfert C, Valis K, Vitkova E, Vollherbst DF, Wick W, Fiehler J, Flottmann F; TENSION Investigators. Arterial Collaterals and Endovascular Treatment Effect in Acute Ischemic Stroke with Large Infarct: A Secondary Analysis of the TENSION Trial. Radiology. 2025 Feb;314(2):e242401. doi: 10.1148/radiol.242401.

Reference Type DERIVED
PMID: 39998372 (View on PubMed)

Thomalla G, Fiehler J, Subtil F, Bonekamp S, Aamodt AH, Fuentes B, Gizewski ER, Hill MD, Krajina A, Pierot L, Simonsen CZ, Zelenak K, Blauenfeldt RA, Cheng B, Denis A, Deutschmann H, Dorn F, Flottmann F, Gellissen S, Gerber JC, Goyal M, Haring J, Herweh C, Hopf-Jensen S, Hua VT, Jensen M, Kastrup A, Keil CF, Klepanec A, Kurca E, Mikkelsen R, Mohlenbruch M, Muller-Hulsbeck S, Munnich N, Pagano P, Papanagiotou P, Petzold GC, Pham M, Puetz V, Raupach J, Reimann G, Ringleb PA, Schell M, Schlemm E, Schonenberger S, Tennoe B, Ulfert C, Valis K, Vitkova E, Vollherbst DF, Wick W, Bendszus M; TENSION Investigators. Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial. Lancet Neurol. 2024 Sep;23(9):883-892. doi: 10.1016/S1474-4422(24)00278-3. Epub 2024 Jul 26.

Reference Type DERIVED
PMID: 39074480 (View on PubMed)

Roaldsen MB, Jusufovic M, Berge E, Lindekleiv H. Endovascular thrombectomy and intra-arterial interventions for acute ischaemic stroke. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD007574. doi: 10.1002/14651858.CD007574.pub3.

Reference Type DERIVED
PMID: 34125952 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TENSION

Identifier Type: -

Identifier Source: org_study_id